We found that MAGE-A6 and MAGE-A11 are highly expressed in BC tissues with high-grade malignancy, therefor it is promising interest to establish the BC immunotherapy for restricting tumor cells through activating specific CD8+ T cells (cytotoxic T lymphocyte; CTL) against tumor cells expressing MAGE-A6 or MAGE-A11. Here, CD8A is linked to breast cancer.